Journey Medical Corporation announced a contract with the third major GPO, expanding Emrosi™ payer access from approximately 100 million to over 150 million commercial lives as of April 1, 2026.
Key takeaways
Secured contract with third major GPO for Emrosi™, achieving ~85% U.S. commercial lives access.
Payer access expanded from ~100 million to over 150 million commercial lives effective April 1, 2026.
Emrosi™ treats inflammatory lesions of rosacea in adults.
Expanded coverage expected to drive prescription demand growth and formulary adoption.
Less reliance on co-pay program anticipated, improving brand profitability.